Alan D. Irvine

36.7k total citations · 14 hit papers
298 papers, 17.2k citations indexed

About

Alan D. Irvine is a scholar working on Dermatology, Immunology and Allergy and Physiology. According to data from OpenAlex, Alan D. Irvine has authored 298 papers receiving a total of 17.2k indexed citations (citations by other indexed papers that have themselves been cited), including 171 papers in Dermatology, 116 papers in Immunology and Allergy and 60 papers in Physiology. Recurrent topics in Alan D. Irvine's work include Dermatology and Skin Diseases (155 papers), Allergic Rhinitis and Sensitization (94 papers) and Food Allergy and Anaphylaxis Research (61 papers). Alan D. Irvine is often cited by papers focused on Dermatology and Skin Diseases (155 papers), Allergic Rhinitis and Sensitization (94 papers) and Food Allergy and Anaphylaxis Research (61 papers). Alan D. Irvine collaborates with scholars based in Ireland, United Kingdom and United States. Alan D. Irvine's co-authors include W.H. Irwin McLean, Stephan Weidinger, Aileen Sandilands, Sinéad Langan, Gráinne M. O’Regan, Donald Y.M. Leung, Thomas Bieber, Lisa A. Beck, Maeve A. McAleer and Kenji Kabashima and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Alan D. Irvine

274 papers receiving 16.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atopic dermatitis

2020 1.2k citations Alan D. Irvine, Stephan Weidinger et al. profile →
Atopic dermatitis

2018 1.1k citations Stephan Weidinger, Lisa A. Beck et al. profile →
Filaggrin Mutations Associated with Skin and Allergic Diseases

2011 826 citations Alan D. Irvine, W.H. Irwin McLean et al. profile →
Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris

2006 681 citations Alan D. Irvine, W.H. Irwin McLean et al. profile →
Filaggrin in the frontline: role in skin barrier function and disease

2009 616 citations Alan D. Irvine, W.H. Irwin McLean et al. profile →
Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome

2000 599 citations Alan D. Irvine et al. profile →
Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations

2006 453 citations Stephan Weidinger, Alan D. Irvine et al. Journal of Allergy and Clinical Immunology profile →
The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation

2020 406 citations Alan D. Irvine et al. profile →
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

2021 350 citations Emma Guttman‐Yassky, Henrique D. Teixeira et al. profile →
Staphylococcus aureus and Atopic Dermatitis: A Complex and Evolving Relationship

2017 348 citations Joan A. Geoghegan, Alan D. Irvine et al. profile →
The microbiome in patients with atopic dermatitis

2018 345 citations Amy S. Paller, Alan D. Irvine et al. Journal of Allergy and Clinical Immunology profile →
The atopic march and atopic multimorbidity: Many trajectories, many pathways

2018 281 citations Amy S. Paller, Alan D. Irvine et al. Journal of Allergy and Clinical Immunology profile →
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

2023 162 citations Jonathan I. Silverberg, Emma Guttman‐Yassky et al. profile →
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

2023 124 citations Gerd R Burmester, Stanley Cohen et al. RMD Open profile →

Peers

Countries citing papers authored by Alan D. Irvine

Since Specialization

Citations

This map shows the geographic impact of Alan D. Irvine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan D. Irvine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan D. Irvine more than expected).

Fields of papers citing papers by Alan D. Irvine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan D. Irvine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan D. Irvine. The network helps show where Alan D. Irvine may publish in the future.

Co-authorship network of co-authors of Alan D. Irvine

This figure shows the co-authorship network connecting the top 25 collaborators of Alan D. Irvine. A scholar is included among the top collaborators of Alan D. Irvine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan D. Irvine. Alan D. Irvine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age 2025 ·The Journal of Allergy and Clinical Immunology In Practice ·Michael J. Cork, Mette Deleuran, Bob Geng, Jonathan I. Silverberg, Eric L. Simpson, Linda Stein Gold, Alan D. Irvine, William Romero, Hernán Valdez, Haiyun Fan, (unknown)	3
2	Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy 2025 ·Dermatology and Therapy ·(unknown), Thomas Bieber, Amy S. Paller, Lisa A. Beck, Masahiro Kamata, L. Puig, Marni Wiseman, Khaled Ezzedine, Alan D. Irvine, Peter Foley, J.Q. Del Rosso, Linda Stein Gold, (unknown), Martín Dossenbach, Gaia Gallo, (unknown), Marta Casillas, (unknown), (unknown), Raj Chovatiya	7
3	Growth Analysis in Children Aged 6 to 11 Years and Adolescents Aged 12 to 17 Years With Moderate-To-Severe Atopic Dermatitis and Impact of 16 Weeks of Dupilumab Treatment on Height 2025 ·Journal of Allergy and Clinical Immunology ·Alan D. Irvine, Amy S. Paller, Elaine C. Siegfried, Michael J. Cork, Lisa A. Beck, Zhen Chen, C. Peralta, (unknown), (unknown), Sonya Cyr	2
4	Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions 2025 ·Allergy ·Marjolein de Bruin‐Weller, Celeste M. Boesjes, (unknown), Lisa A. Beck, Alan D. Irvine, Christian Vestergaard, Marlies de Graaf, Femke van Wijk, Daphne S. Bakker, Stephan Weidinger	1
5	Infant palmar hyperlinearity and type 2 inflammatory markers predict atopic dermatitis at 1 year of age 2025 ·Journal of the European Academy of Dermatology and Venereology ·(unknown), Anne‐Sofie Halling, (unknown), Trine Gerner, (unknown), (unknown), (unknown), Lone Skov, Simon Trautner, (unknown), Alexander Egeberg, Ivone Jakaša, Alan D. Irvine, Sanja Kežić, Jacob P. Thyssen	1
6	A patient’s experience of progressive hemifacial atrophy 2024 ·Clinical and Experimental Dermatology ·(unknown), Rosemarie Watson, Dylan J. Murray, Alan D. Irvine	0
7	693 - Efficacy and safety of orismilast, a potent PDE4B/D inhibitor, in adults with moderate-to-severe atopic dermatitis: a phase 2b randomized, double-blind, placebo-controlled clinical trial (ADESOS) 2024 ·British Journal of Dermatology ·Jonathan I. Silverberg, Lawrence F. Eichenfield, Andrew Blauvelt, Alan D. Irvine, Richard G. Langley, (unknown), Richard B. Warren, Lars E. French, (unknown), Anna Carlsson, Morten Lind Jensen, Morten Otto Alexander Sommer, Kim Kjøller, Eric L. Simpson	1
8	Real‐world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study 2023 ·Journal of the European Academy of Dermatology and Venereology ·Kilian Eyerich, Melinda Gooderham, (unknown), Stephen Shumack, Pedro Mendes‐Bastos, Valéria Aoki, Michela Ortoncelli, Jonathan I. Silverberg, Henrique D. Teixeira, (unknown), Brian Calimlim, (unknown), Cristina Sancho, (unknown), Alan D. Irvine	26
9	Novel mixed-method, inclusive protocol involving global key stakeholders, including carers as experts, to co-develop relevant Caregiver-Reported Outcome Domains (CRODs) in skin disease 2023 ·BMJ Open ·(unknown), Gerard Leavey, (unknown), Amy S. Paller, Alan D. Irvine, Fiona Browne, Jemima E. Mellerio, Anthony Bewley	1
10	Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis breakdown → 2023 ·RMD Open ·Gerd R Burmester, Stanley Cohen, Kevin Winthrop, Peter Nash, Alan D. Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P. Lacerda, Hannah Palac, Tim Shaw, Philip J. Mease, Emma Guttman‐Yassky	124
11	The role of Janus kinase signaling in the pathology of atopic dermatitis 2023 ·Journal of Allergy and Clinical Immunology ·Emma Guttman‐Yassky, Alan D. Irvine, Patrick M. Brunner, Brian Kim, Mark Boguniewicz, Julie Parmentier, Andrew M. Platt, Kenji Kabashima	47
12	Parental atopy and risk of atopic dermatitis in the first two years of life in the BASELINE birth cohort study 2022 ·Pediatric Dermatology ·Cathal O’Connor, Vicki Livingstone, Jonathan O’B Hourihane, Alan D. Irvine, Geraldine B. Boylan, Deirdre M. Murray	9
13	Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies 2022 ·Journal of Allergy and Clinical Immunology ·Emma Guttman‐Yassky, Jacob P. Thyssen, Jonathan I. Silverberg, Kim Papp, Amy S. Paller, Stephan Weidinger, Hwanhee Hong, Barbara A. Hendrickson, (unknown), Allan R. Tenorio, Barry Ladizinski, Alvina D. Chu, John Liu, Alan D. Irvine	43
14	A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis 2021 ·Allergy ·(unknown), Alan D. Irvine, Reiko Tanaka	21
15	Topical corticosteroids normalize both skin and systemic inflammatory markers in infant atopic dermatitis 2020 ·British Journal of Dermatology ·Maeve A. McAleer, Ivone Jakaša, Nicholas Stefanovic, W.H. Irwin McLean, (unknown), Alan D. Irvine	27
16	The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group 2019 ·British Journal of Dermatology ·Helen Alexander, Amy S. Paller, Claudia Traidl‐Hoffmann, Lisa A. Beck, Anna De Benedetto, Sandipan Dhar, Giampiero Girolomoni, Alan D. Irvine, Phyllis I. Spuls, John Su, Jacob P. Thyssen, Christian Vestergaard, Thomas Werfel, Andreas Wollenberg, Mette Deleuran, Carsten Flohr	123
17	RASA1 mosaic mutations in patients with capillary malformation-arteriovenous malformation 2019 ·Journal of Medical Genetics ·Nicole Revençu, (unknown), Marie Ravoet, Raphaël Helaers, Pascal Brouillard, (unknown), (unknown), Marion Gérard, Veronika Dvořáková, Alan D. Irvine, Louis Boon, Miikka Vikkula	46
18	The widespread use of topical antimicrobials enriches for resistance inStaphylococcus aureusisolated from patients with atopic dermatitis 2018 ·British Journal of Dermatology ·Catriona P. Harkins, Maeve A. McAleer, Désirée E. Bennett, M. McHugh, (unknown), Kerry A. Pettigrew, Katarína Oravcová, Julian Parkhill, Charlotte M. Proby, Robert Dawe, Joan A. Geoghegan, Alan D. Irvine, Matthew T. G. Holden	39
19	Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement 2017 ·British Journal of Dermatology ·Aaron M. Drucker, Kilian Eyerich, Marjolein de Bruin‐Weller, Jacob P. Thyssen, Phyllis I. Spuls, Alan D. Irvine, Giampiero Girolomoni, Sandipan Dhar, Carsten Flohr, Dédée F. Murrell, Amy S. Paller, Emma Guttman‐Yassky	130
20	BSO volume 57 issue 2 Front matter 1994 ·Bulletin of the School of Oriental and African Studies ·(unknown), (unknown), (unknown), (unknown), (unknown), William Hale, Gabriel Warburg, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Donal Cruise O’Brien, (unknown), Alan D. Irvine, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact